Investors

  • 2020-12-02
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON RECOMMENDED BREAKTHROUGH THERAPY DESIGNATION FOR NEFECON FOR THE TREATMENT OF IGA NEPHROPATHY
  • 2020-11-10
    VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON LICENSING PARTNER CALLIDITAS THERAPEUTICS REPORTING TOPLINE RESULTS FROM PIVOTAL PHASE 3 NEFIGARD TRIAL
  • 2020-11-06
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2020
  • 2020-11-03
    VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE OF FIRST PATIENT DOSED IN PHASE 2B REGISTRATION CLINICAL TRIAL OF TRODELVY TM (SACITUZUMAB GOVITECAN) FOR THE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN CHINA
  • 2020-11-02
    VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON APPROVAL OF CLINICAL TRIAL APPLICATION BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR PHASE 3 REGISTRATION TRIAL OF TRODELVY TM FOR METASTATIC BREAST CANCER IN CHINA
  • 2020-11-01
    ANNOUCEMENT OF FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD
  • 2020-10-27
    VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON THE COMPLETION OF PHASE 3 BRIDGING CLINICAL TRIAL OF XERAVA TM (ERAVACYCLINE) FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN CHINA
  • 2020-10-08
    ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS
 Copyright Everest Medicines 2020   苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers